LSV Asset Management boosted its holdings in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 0.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,471,718 shares of the biopharmaceutical company’s stock after purchasing an additional 5,300 shares during the quarter. LSV Asset Management owned approximately 5.24% of Sucampo Pharmaceuticals worth $44,367,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of SCMP. Trexquant Investment LP acquired a new stake in shares of Sucampo Pharmaceuticals in the third quarter valued at approximately $122,000. Nine Chapters Capital Management LLC acquired a new stake in Sucampo Pharmaceuticals during the third quarter worth $127,000. JPMorgan Chase & Co. acquired a new stake in Sucampo Pharmaceuticals during the second quarter worth $117,000. Aperio Group LLC acquired a new stake in Sucampo Pharmaceuticals during the third quarter worth $137,000. Finally, Stifel Financial Corp acquired a new stake in Sucampo Pharmaceuticals during the second quarter worth $131,000. Institutional investors own 67.09% of the company’s stock.
Several research firms have issued reports on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Leerink Swann reaffirmed a “market perform” rating and issued a $15.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Zacks Investment Research cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Nomura started coverage on Sucampo Pharmaceuticals in a report on Monday, December 18th. They issued a “buy” rating and a $43.00 target price for the company. Finally, B. Riley lifted their target price on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, December 6th. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $20.25.
Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) remained flat at $$18.00 during mid-day trading on Tuesday. 956,100 shares of the stock were exchanged, compared to its average volume of 2,557,332. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals, Inc. has a 12 month low of $9.30 and a 12 month high of $18.75. The stock has a market cap of $849.02, a price-to-earnings ratio of -5.47, a PEG ratio of 5.06 and a beta of 1.38.
In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the transaction, the insider now owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.13% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/lsv-asset-management-grows-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.